Aindo generates synthetic structured data: artificial records produced by generative models that reproduce the statistical behaviour of a real dataset while containing no actual personal information, so the data can be shared, pooled and analysed without triggering the privacy constraints that keep most clinical datasets locked in place. The company's argument is that data access, not modelling capability, is the binding constraint on applied AI in medicine, where records are not only sensitive but fragmented, hard to reach and largely unused for research and validation. Its platform serves hospitals, health authorities, pharma and life sciences teams, supporting real-world evidence studies, synthetic control arms in clinical trials, deep-phenotyped synthetic patients for precision medicine and the training of clinical AI, and it is built around the European Health Data Space regulation rather than retrofitted to it. Recent work includes a three-year agreement with IQVIA Italy on synthetic health data, membership of AICROplus, and a clinical decision support model for heart failure developed with Centro Cardiologico Monzino. Founded in 2018 as a spin-off of SISSA in Trieste by Daniele Panfilo (CEO), Sebastiano Saccani (Head of R&D) and Borut Svara (CTO), Aindo has patented its generation technology, raised a EUR6 million Series A in 2023 led by United Ventures with Vertis SGR, won a EUR2.1 million EIC Accelerator grant in 2025 as one of 71 selected from 1,211 applicants, and became the first company in Europe certified under Europrivacy for synthetic data in healthcare.